Specific phobia of amyotrophic lateral sclerosis (ALS phobia): 233 observations over 18 years (2006–2024)
- Authors: Levitsky G.N.1, Berdalin A.B.2, Gilod V.M.3, Levitsky A.S.4, Kovrazhkina E.A.5, Shovkoplyas E.L.1, Gilvanova O.V.6, Makashova E.S.6, Polyakov A.V.7, Shestachenko V.V.1, Savko V.A.3, Ermolyeva E.A.3, Galtsev E.V.3, Olivenbaum G.A.1, Vidergoldt О.V.1, Levin O.S.8, Laukart E.B.9
-
Affiliations:
- Gleb Levitsky Clinic with a Private Center for Amyotrophic Lateral Sclerosis
- Alekseev Psychiatric Clinical Hospital No. 1
- Crisis-Psychiatric Department, Yeramishantsev City Clinical Hospital
- Private Psychiatrist, Narcologist and Psychotherapist
- Federal Center for Brain and Neurotechnology of the Federal Medical and Biological Agency of Russia
- Center for Neuromuscular Pathology, A.S. Loginov Moscow Clinical Research Center
- Research Centre for Medical Genetics
- Russian Medical Academy of Continuos Professional Education
- Central Clinical Hospital of the Administrative Directorate of the President of the Russian Federation
- Issue: Vol 32, No 1 (2025)
- Pages: 202-213
- Section: Neurology
- URL: https://journals.eco-vector.com/2073-4034/article/view/679993
- DOI: https://doi.org/10.18565/pharmateca.2025.1.202-213
- ID: 679993
Cite item
Abstract
Background. There have been no new publications on the alsphobia since 2012, but awareness of amyotrophic lateral sclerosis among people with anxiety disorders has increased, as has the incidence of phobic disorders.
Methods. 233 patients with alsphobia were examined in neurological and psychiatric clinics with an assessment of the dynamics at different times using the Hamilton Depression Rating Scale. Neurological and endocrinological diagnoses as causes of «benign fasciculation syndrome» were established by excluding various causes using the methods of collecting anamnesis and follow-up, magnetic resonance imaging, needle and stimulation myography, analysis of creatine phosphokinase levels, genetic analysis for DAT1 gene mutations, and others.
Results. In total, there were 49 patients (22.4%) with a history of other phobias, 35 (16.0%) with panic attacks, 14 (6.9%) with a patient with ALS in the family, 11 (5.2%) doctors, and 11 (5.2%) iatrogenic cases. Thirty-nine (16.7%) patients were diagnosed with neurological diseases, and ten (4.3%) with endocrinological diseases. In total, there were 159 (68.2%) patients who received a psychiatric consultation, and 74 (32.3%) patients who did not. A total of 212 patients were assessed using the HAM-D scale before treatment and 151 after treatment. The sensitivity and specificity of such symptoms of alsphobia as video recording of twitching, twitching in the feet, interpretive delusions and agitation were 55–79% (p<0.001–0.0005). All these symptoms significantly correlated with each other with correlation coefficients from 0.2 to 0.6. The correlation between the duration and the HAM-D score was not significant (p=0.069). According to the ANOVA, the severity of phobia with assessment using Hamilton score, did not differ significantly (p=0.281). The severity of phobia according Hamilton score did not differ significantly depending on the presence of ALS in the family (p=0.594), iatrogenia (p=0.683), or health care workers (p=0.917). In situational anxiety disorders, the percentage of recovered patients was significantly higher than in endogenous diseases (χ2=23.3, p<0.001). The time dynamics in terms of recovery was significant (p<0.0005), but the differences between neurological, mental, and endocrine disorders, both in general (p=0.567) and in dynamics (p=0.436), were insignificant. Mutations in the DAT1 gene were detected in 15 of 20 examined patients. Prescription of therapy with an antidepressant and/or an atypical neuroleptic, thymoleptic did not significantly change the probability of recovery (p=0.172). According to the results of follow-up, one patient developed ALS, and one patient developed spinal amyotrophy (clinical examples are presented).
Conclusion. The judgement of a psychiatrist whether a patient has situation-mediated or endogenous anxiety disorder plays a key role. The prognosis for recovery is more favorable in patients with situational disorders. High sensitivity, specificity, and correlation of specific symptoms of alsphobia are shown. Management of patients with «benign fasciculation syndrome» within the framework of alsphobia should be carried out using a multidisciplinary approach (neurologist, functional diagnostics physician, psychiatrist, endocrinologist).
Full Text

About the authors
Gleb N. Levitsky
Gleb Levitsky Clinic with a Private Center for Amyotrophic Lateral Sclerosis
Author for correspondence.
Email: alsrus@gmail.com
Cand. Sci. (Med.), Neurologist, Functional Diagnostics Doctor, General Director, Gleb Levitsky Clinic with a Private Center for Amyotrophic Lateral Sclerosis, Director of the Nina Levitsksya (Russian) Charity ALS foundation, International Emissary for ALS Patients’ Rights
Russian Federation, MoscowAlexander B. Berdalin
Alekseev Psychiatric Clinical Hospital No. 1
Email: alsrus@gmail.com
Senior Research Fellow
Russian Federation, MoscowVadim M. Gilod
Crisis-Psychiatric Department, Yeramishantsev City Clinical Hospital
Email: alsrus@gmail.com
Cand. Sci. (Med.), Psychiatrist, Head of the Crisis-Psychiatric Department
Russian Federation, MoscowAndrey S. Levitsky
Private Psychiatrist, Narcologist and Psychotherapist
Email: alsrus@gmail.com
Private psychiatrist, Narcologist and Psychotherapist
Russian Federation, MoscowElena A. Kovrazhkina
Federal Center for Brain and Neurotechnology of the Federal Medical and Biological Agency of Russia
Email: alsrus@gmail.com
Cand. Sci. (Med.), Neurologist, Functional Diagnostics Specialist, Employee of the Federal Center
Russian Federation, MoscowElena L. Shovkoplyas
Gleb Levitsky Clinic with a Private Center for Amyotrophic Lateral Sclerosis
Email: alsrus@gmail.com
Psychotherapist
Russian Federation, MoscowOlga V. Gilvanova
Center for Neuromuscular Pathology, A.S. Loginov Moscow Clinical Research Center
Email: alsrus@gmail.com
Neurologist, Functional Diagnostics Specialist, Head of the Center for Neuromuscular Pathology
Russian Federation, MoscowElizaveta S. Makashova
Center for Neuromuscular Pathology, A.S. Loginov Moscow Clinical Research Center
Email: alsrus@gmail.com
Neurologist and Functional Diagnostics Specialist of the Center for Neuromuscular Pathology
Russian Federation, MoscowAlexander V. Polyakov
Research Centre for Medical Genetics
Email: alsrus@gmail.com
Dr. Sci. (Biol.), Professor, Corresponding Member of the Russian Academy of Sciences, Head of the Genetic Laboratory, Research Centre
Russian Federation, MoscowVictoria V. Shestachenko
Gleb Levitsky Clinic with a Private Center for Amyotrophic Lateral Sclerosis
Email: alsrus@gmail.com
Deputy Director for Development
Russian Federation, MoscowVarvara A. Savko
Crisis-Psychiatric Department, Yeramishantsev City Clinical Hospital
Email: alsrus@gmail.com
Psychiatrist, Crisis Psychiatric Department
Russian Federation, MoscowElena A. Ermolyeva
Crisis-Psychiatric Department, Yeramishantsev City Clinical Hospital
Email: alsrus@gmail.com
Psychiatrist, Crisis Psychiatric Department
Russian Federation, MoscowEvgeny V. Galtsev
Crisis-Psychiatric Department, Yeramishantsev City Clinical Hospital
Email: alsrus@gmail.com
Psychiatrist, Crisis Psychiatric Department
Russian Federation, MoscowGrigory A. Olivenbaum
Gleb Levitsky Clinic with a Private Center for Amyotrophic Lateral Sclerosis
Email: alsrus@gmail.com
Assistant Director, Gleb Levitsky Clinic
Russian Federation, MoscowОleg V. Vidergoldt
Gleb Levitsky Clinic with a Private Center for Amyotrophic Lateral Sclerosis
Email: alsrus@gmail.com
Assistant Director, Gleb Levitsky Clinic
Russian Federation, MoscowOleg S. Levin
Russian Medical Academy of Continuos Professional Education
Email: alsrus@gmail.com
Dr. Sci. (Med.), Professor, Head of the Department of Neurology and Reflexology
Russian Federation, MoscowElena B. Laukart
Central Clinical Hospital of the Administrative Directorate of the President of the Russian Federation
Email: alsrus@gmail.com
Cand. Sci. (Med.), Neurologist, Head of the Neurological Department
Russian Federation, MoscowReferences
- Левицкий Г.Н., Гилод В.М., Левин О.С. Специфическая фобия БАС – алсфобия. Журнал неврологии и психиатрии им. С.С. Корсакова. 2012;8:4–7. [Levitsky G.N., Gilod V.M., Levin O.S. A specific phobia of amyotrophic lateral sclerosis (ALS phobia). S.S. Korsakov Journal of Neurology and Psychiatry. 2012;112(8):4-6. (In Russ.)].
- Levitsky G., Gilod V., Levin O. Specific phobia of ALS. Abstracts from the 23rd ALS MND Symposium. Amyotroph Lateral Sclerosis. 2012;13:22. doi: 10.3109/17482968.2012.721231/035.
- Xu L., Liu T., Liu L., et al. Global variation in prevalence and incidence of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol. 2020;267(4):944–953. doi: 10.1007/s00415-019-09652-y.
- Jaiswal A., Manchanda S., Gautam V., et al. Burden of internet addiction, social anxiety and social phobia among University students, India. J Family Med Prim Care. 2020;9(7):3607–3612. doi: 10.4103/jfmpc.jfmpc_360_20.
- Bandelow B., Michaelis S.. Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci. 2015;17(3):327–35. doi: 10.31887/DCNS.2015.17.3/bbandelow.
- Sindoni A., Rodolico C., Pappalardo M.A., et al. Hypothyroid myopathy: A peculiar clinical presentation of thyroid failure. Review of the literature. Rev Endocr Metab Disord. 2016;17(4):499–519. doi: 10.1007/s11154-016-9357-0.
- Cui H., Zhang X. Thyrotoxic myopathy: research status, diagnosis, and treatment. Endokrynol Pol. 2022;73(1):157–162. doi: 10.5603/EP.a2022.0004.
- Silberschmidt A.L., Sponheim S.R. Personality in relation to genetic liability for schizophrenia and bipolar disorder: differential associations with the COMT Val 108/158 Met polymorphism. Schizophr Res. 2008;100(1-3):316–24. doi: 10.1016/j.schres.2007.12.467.
- Jasiewicz A., Rubis B., Samochowiec J., et al. DAT1 methylation changes in alcohol-dependent individuals vs. controls. J Psychiatr Res. 2015;64:130–3. doi: 10.1016/j.jpsychires.2015.03.007.
- Walter T.R. Benign fasciculation syndrome. J Pain Palliat Care Pharmacother. 2015;29(1):54–5. doi: 10.3109/15360288.2014.997856.
- Sim M., Reid D., Pallett J., Gordon E. The Hamilton rating scale. An assessment bases on a dothiepin (prothiaden) versus imipramine (Tofranil) clinical trial. Int Pharmacopsychiatry. 1975;10(3):142–8. doi: 10.1159/000468184.
- Гофман А.А., Колочихин К.С. Фобии: их разновидности, причины возникновения и влияние на поведение человека. Ученые записки института имени П.Ф. Лесгафта. 2022;12(214):644–650. [Goffman A.A., Kolochikhin K.S. Phobias: their types, causes and influence on human behavior. Scientific notes of the P.F. Lesgaft Institute. 2022;12(214):644–650. (In Russ.)]. doi: 10.34835/issn23088-1961/2022/h644-650.
- Воробьев С.С. Фобии: понятие, виды, причины и влияние семьи на формирование фобий. Систематические исследования индивидуально растущего человека как субъекта образования. Материалы всероссийского конгресса с международным участием, научно-практическая конференция. Пермь, 2022. С. 185–189. [Vorobyov S.S. Phobias: concept, types, causes and influence of the family on the formation of phobias. Systematic studies of an individually growing person as a subject of education. Proceedings of the All-Russian Congress with International Participation, Scientific and Practical Conference. Perm, 2022. P. 185–189. (In Russ.)].
- Дамулин И.В., Оразмурадов Г.О. Неврологические нарушения при гипотиреозе. Журнал неврологии и психиатрии им. С.С. Корсакова. 2011;111(3):82–86. [Damulin I.V,. Orazmuradov G.O. Neurologic disorders in hypothyreosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2011;111(3):82–86. (In Russ.)].
- Друк И.В., Урасова Ф.К., Насекина О.В., Агишева К.А. Алекситимия и тревожно-депрессивные расстройства у пациентов с медикаментозно компенсированным и впервые выявленным манифестным гипотиреозом. Эндокринология: новости, мнения, обучение. 2024;13(1):35–44. [Druk I.V., Urazova F.K., Nasekina O.V., Agisheva K.A. Alexithymia and anxiety-depressive disorders in patients with controlled and newly diagnosed manifest hypothyroidism. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2024;13(1):35–44. (In Russ.)]. doi: 10.33029/2304-9529-2024-13-1-35-44.
- Pulay A.J., Stinson F.S., Dawson D.A., et al: Prevalence, correlates, disability, and comorbidity of DSM-IV schizotypal personality disorder: Results from the wave 2 national epidemiologic survey on alcohol and related conditions. Prim Care Companion J Clin Psychiatry. 2009;11(2):53–67. doi: 10.4088/pcc.08m00679.
- Кадырова Л.Р., Губеев Б.Э., Рахматуллина Э.Ф. Возможности лечения ситуационной тревожности в практике невролога. Медицинский Совет. 2023;(21):161–167. [Kadyrova L.R., Gubeev B.Е., Rakhmatullina E.F. Treatment options for situational anxiety in the neurology physician practice. Meditsinskiy Sovet. 2023;17(21):161–167. (In Russ.)]. doi: 10.21518/ms2023-413.
- Blexrud M.D., Windebank A.J., Daube J.R. Long-term follow-up of 121 patients with benign fasciculations. J Neurol. 1993;34(4):622–5.
- Carvalho M., Swash M. Cramps, muscle pain and fasciculations: Not always benign? Neurology. 2004;63(4):721–3.
- Singh V., Gibson J., Mc Lean B., et al. Fasciculation and cramps: How benign? Report of four cases progressing into ALS. J Neurol. 2011;258(4):573–8.
Supplementary files
